Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:38 PM
Ignite Modification Date:
2025-12-24 @ 11:38 PM
NCT ID:
NCT03572556
Eligibility Criteria:
Inclusion Criteria:
* Person who has given consent
* Adult
* Person capable of understanding spoken and written French
"Patient" group:
* Certain HHT (3 or 4 Curacao criteria - Appendix 2):
* Recurring epistaxis
* Telangiectasia of the skin or mouth
* Family hereditary context
* Arteriovenous visceral malformations
* Causal mutation identified
* Person capable of completing monthly epistaxis charts
"Control" group :
\- Control subjects will be matched to patients for age (+/- 6 years) and sex.
Exclusion Criteria:
* Person not affiliated to a national health insurance scheme
* Pregnant or breastfeeding woman
* Protected adult
* Hemoglobin levels less than 9 g/dl in the last 15 days
* Progressive or recent infectious disease, autoimmune disease or cancer (less than 6 months)
* Immunosuppressive treatment in progress or recent (less than 6 months), including systemic steroid therapy. The use of inhaled or topical steroids is not an exclusion criterion.
* Treatment in progress or stopped less than 6 months ago or to be introduced within the next 3 months of the following medications:
* bevacizumab
* tranexamic acid
* dipeptidyl peptidase 4 inhibitors (diabetic patient)
* beta-blockers (hypertensive patient)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03572556
Study Brief:
Protocol Section:
NCT03572556